Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Blaze Pizza Introduces First-Ever Kids Menu Just in Time for Back-to-School

August 27, 2026

Police investigate triple vehicle fire in Toronto neighbourhood as arson

August 27, 2026

Truepic and OtterBox partner to accelerate warranty claims with authentication in under a minute

August 27, 2026

SERVPRO Franchisees Smash Fundraising Record for First Responders Children’s Foundation

August 27, 2026

Google launches Pokémon Sleep special-edition Fitbit Air

August 27, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Oncology Clinical Trials Market Forecast 2026-2035 – AI Revolutionizes Oncology Clinical Trials: Boosts Recruitment, Optimizes Protocols
Press Release

Oncology Clinical Trials Market Forecast 2026-2035 – AI Revolutionizes Oncology Clinical Trials: Boosts Recruitment, Optimizes Protocols

By News RoomMarch 23, 20263 Mins Read
Oncology Clinical Trials Market Forecast 2026-2035 – AI Revolutionizes Oncology Clinical Trials: Boosts Recruitment, Optimizes Protocols
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, March 23, 2026 (GLOBE NEWSWIRE) — The “Oncology Clinical Trials Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035” has been added to ResearchAndMarkets.com’s offering.

The global oncology clinical trials market continues to expand, driven by rising investment in research and an urgent demand for groundbreaking cancer treatments. Valued at approximately USD 14.95 billion in 2025, the market is projected to grow to USD 25.61 billion by 2035, with a CAGR of 5.53% from 2026 to 2035. This trajectory underscores the breadth of oncology research programs worldwide and the pharmaceutical industry’s focus on cancer drug development.

The growing incidence of cancer globally is a key factor behind this expansion. Factors like aging populations, environmental exposures, and lifestyle-related risks contribute to increased cancer prevalence, thus fuelling demand for effective therapies. Consequently, pharmaceutical companies and research institutions are significantly ramping up investment in oncology clinical trials, aiming to expedite the discovery and approval of new therapies.

Noteworthy Market Developments

The market is highly competitive, with prominent pharmaceutical companies like AstraZeneca, Merck & Co., Roche, and Novartis leading the way. These companies constitute about 35% of the oncology clinical trial pipeline as of 2025. AstraZeneca, notably, has made significant strides in the antibody-drug conjugate sector, bolstered by the success of Enhertu, reinforcing its stronghold in oncology innovation.

Core Growth Drivers

The increasing global cancer burden intensifies the market’s momentum. As cancer cases surge, healthcare systems face mounting pressure to fast-track the development of innovative treatments aimed at improving patient outcomes. This scenario propels pharmaceutical firms and research organizations to expand clinical trial programs for exploring novel treatment strategies and bringing advanced therapies to market swiftly.

Emerging Opportunity Trends

Artificial intelligence is transforming clinical trials by enhancing crucial processes in oncology research. AI technologies optimize patient recruitment, refine protocol design, and improve clinical data management, facilitating a more efficient trial process and boosting research productivity.

Barriers to Optimization

Patient recruitment poses a significant challenge, with only about 5% of adult cancer patients partaking in trials. This gap hinders trial progress, elongates development timelines, and increases the costs of bringing new oncology treatments to market.

Detailed Market Segmentation

By Phase Type, Phase III trials account for over 48.89% of the market share, being the most resource-intensive. Interventional studies dominate with over 71% share due to their complex nature, requiring substantial logistical coordination and regulatory oversight.

Geographical Breakdown

North America leads the market, notable for its extensive research infrastructure and regulatory systems that support large-scale clinical trials. As of early 2024, North America represents more than 58% of radiation oncology studies, with oncology remaining a focal area.

Leading Market Participants Profiled

  • AbbVie Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Charles River Laboratories
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • IQVIA
  • ICON plc
  • Johnson & Johnson
  • Labcorp Drug Development
  • Medpace Holdings
  • Merck & Co., Inc.
  • Novartis AG
  • Parexel International
  • Pfizer Inc.
  • Syneos Health
  • Takeda Pharmaceutical
  • Thermo Fisher Scientific
  • Wuxi Clinical CRO

Key Attributes

Report Attribute Details
No. of Pages 260
Forecast Period 2025-2035
Estimated Market Value (USD) in 2025 $14.95 Billion
Forecasted Market Value (USD) by 2035 $25.61 Billion
Compound Annual Growth Rate 5.5%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/k8501r

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Oncology Clinical Trials Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Blaze Pizza Introduces First-Ever Kids Menu Just in Time for Back-to-School

Truepic and OtterBox partner to accelerate warranty claims with authentication in under a minute

SERVPRO Franchisees Smash Fundraising Record for First Responders Children’s Foundation

Technology Empowers Elegance: LEPAS Redefines the New Energy Mobility Experience

Crypto News: Pepeto Reveals Presale Round Sold Out Hours Early as the XRP Price Prediction Targets $6.40

Ampersand Capital Partners Recognized Among GrowthCap's Top Private Equity Firms of 2026

SimpleSwap Marks a Year Inside Exodus Wallet, Ships Five Partner Updates With No Integration Changes

BTCC Exchange VIP Program Posts $11 Billion in Q2 Trading Volume, Saves Elite Traders Over $1.56M in Fees

6th Monaco Smart & Sustainable Marina Rendezvous 20 and 21 September 2026, two days focused on issues transforming marinas

Editors Picks

Police investigate triple vehicle fire in Toronto neighbourhood as arson

August 27, 2026

Truepic and OtterBox partner to accelerate warranty claims with authentication in under a minute

August 27, 2026

SERVPRO Franchisees Smash Fundraising Record for First Responders Children’s Foundation

August 27, 2026

Google launches Pokémon Sleep special-edition Fitbit Air

August 27, 2026

Latest News

Technology Empowers Elegance: LEPAS Redefines the New Energy Mobility Experience

August 27, 2026

Crypto News: Pepeto Reveals Presale Round Sold Out Hours Early as the XRP Price Prediction Targets $6.40

August 27, 2026

Ampersand Capital Partners Recognized Among GrowthCap's Top Private Equity Firms of 2026

August 27, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version